News Focus
News Focus
icon url

misiu143

04/14/22 10:06 PM

#9169 RE: Rotten Johnny #9168

There is nothing as a game changer in this drug...leronlimab showed results in critical , patients on the ventilators and ECMO , 82% mortality benefit above all the toxic , drugs with minimal efficacy approved by FDA ...

This drug showed nothing much really ...if you compare to leronlimab and even to the small studies with Tollovir ...

I feel about this drug and this study as an author of this article below ..They saying 45% on SOC and placebo died ..well ....45% ????? please show me any other study with this numbers ....

As always all imo...

https://insiderfinancial.com/verus-nasdaq-veru-repurposed-covid-19-drug-facing-uphill-battle-for-eua/183126/



icon url

GreeseMonkey

04/15/22 1:13 AM

#9172 RE: Rotten Johnny #9168

Game changer? Are you kidding? Mortality reduced by half? What about the other half that die? I'd rather take my chances with Tollovir, or even Tollovid, than risk my outcome on the flip of a coin (50/50) with Sabizabulin. It may be a game changer for the moment as there isn't an approved drug with better mortality reduction, but Tollovir will kick its ass and it's just a matter of time. And for those who continue to claim Covid is almost over, they have no clue about the reality of it. Talk to doctors and nurses and they will tell you a completely different story than what the government and media are telling us. You have to remember, there are elections coming up, and they need to show how they have defeated Covid, even if the figures are imaginary.

The world is ready and longing for Tollovir. Todos will get there and change the world. The road to success starts with the first EUA. Mark this post.
icon url

arpemd

04/16/22 10:54 AM

#9180 RE: Rotten Johnny #9168

mebbe, but

https://seekingalpha.com/pr/18647492-todos-medical-and-nlc-pharma-announce-primary-and-secondary-endpoints-met-in-nlc-vminus-01

JP, note those words: "interim analysis", meaning the trial was closed early due to endpoints being reached extremely quickly.

that's the good news. The bad news is, that the trial REALLY needs more peeps a la sabizabulin to catch the eye of reg agencies and other peeps.